About this trial
To investigate the clinical utility of both 3D and 2D artificial intelligence reconstruction echocardiography (V-echo and L-echo) assessment against conventional echocardiography and clinical cardiovascular magnetic resonance (CMR) imaging for the characterisation of cardiac function and detection of cardiotoxicity in patients receiving chemotherapy.
Diagnostic accuracy of V-echo and L-echo for quantification of cardiac chamber sizes and systolic function (left ventricular ejection fraction (LVEF) and strain analyses) versus conventional echocardiography (C-echo) and CMR; workflow measures including imaging temporal measures of image acquisition, registration and analysis versus conventional approaches; survey of markers of acceptability by patients and sonographers; cost effectiveness analysis of V-echo and L-echo versus conventional echocardiography; assessment of the relationship between 3D strain parameters derived from V-echo data, 2D strain parameters derived from L-echo and correlation with conventional markers of cardiac function, namely LVEF and global longitudinal strain.
Eligibility criteria
Qualifiers
Aged 18 years or older
Received potentially cardiotoxic chemotherapy
Participant requires echocardiography surveillance as standard current practice
Disqualifiers
Below the age of 18 years old
Inability to give informed consent
Implanted cardiac devices
Not having received cardiotoxic chemotherapy. Ineligible patients and patients not wishing to take part will be excluded, the reasons for this will be recorded and baseline CONSORT demographics noted including age, gender, ethnicity.
Trial design
Treatments tested in this trial
- V-echo
- L-echo
Treatment groups
Locations
Sponsors and collaborators
The Royal Wolverhampton Hospitals NHS Trust
Lead sponsor
VentriPoint Diagnostics Ltd.
Collaborator